Fused heterocyclic compounds

Fused heterocyclic compounds

1 2 33 12 3 12 3 244441-4 4 There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein Ris an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; Ris an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Aso, Kazuyoshi, Mochizuki, Michiyo, Gyorkos, Albert Charles, Corrette, Christopher Peter, Cho, Suk Young, Pratt, Scott Alan, Siedem, Christopher Stephen
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Aso, Kazuyoshi
Mochizuki, Michiyo
Gyorkos, Albert Charles
Corrette, Christopher Peter
Cho, Suk Young
Pratt, Scott Alan
Siedem, Christopher Stephen
description 1 2 33 12 3 12 3 244441-4 4 There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein Ris an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; Ris an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or -NR- (wherein Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); Y, Yand Yare each an optionally substituted carbon or a nitrogen, provided that one or less of Y, Yand Yis nitrogen; and Z is a bond, -CO-, oxygen, sulfur, -SO-, -SO-, -NR-, -NR-alk-, -CONR- or -NRCO- (wherein alk is an optionally substituted Calkylene and Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); or a salt thereof or a prodrug thereof.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_08163935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>08163935</sourcerecordid><originalsourceid>FETCH-uspatents_grants_081639353</originalsourceid><addsrcrecordid>eNrjZJBxKy1OTVHISC1JLcpPrkzOyUxWSM7PLcgvzUsp5mFgTUvMKU7lhdLcDApuriHOHrqlxQWJJal5JcXx6UWJIMrAwtDM2NLY1JgIJQCkhyUE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Fused heterocyclic compounds</title><source>USPTO Issued Patents</source><creator>Aso, Kazuyoshi ; Mochizuki, Michiyo ; Gyorkos, Albert Charles ; Corrette, Christopher Peter ; Cho, Suk Young ; Pratt, Scott Alan ; Siedem, Christopher Stephen</creator><creatorcontrib>Aso, Kazuyoshi ; Mochizuki, Michiyo ; Gyorkos, Albert Charles ; Corrette, Christopher Peter ; Cho, Suk Young ; Pratt, Scott Alan ; Siedem, Christopher Stephen ; Takeda Pharmaceutical Company Limited</creatorcontrib><description>1 2 33 12 3 12 3 244441-4 4 There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein Ris an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; Ris an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or -NR- (wherein Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); Y, Yand Yare each an optionally substituted carbon or a nitrogen, provided that one or less of Y, Yand Yis nitrogen; and Z is a bond, -CO-, oxygen, sulfur, -SO-, -SO-, -NR-, -NR-alk-, -CONR- or -NRCO- (wherein alk is an optionally substituted Calkylene and Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); or a salt thereof or a prodrug thereof.</description><language>eng</language><creationdate>2012</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8163935$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,780,802,885,64039</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8163935$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Aso, Kazuyoshi</creatorcontrib><creatorcontrib>Mochizuki, Michiyo</creatorcontrib><creatorcontrib>Gyorkos, Albert Charles</creatorcontrib><creatorcontrib>Corrette, Christopher Peter</creatorcontrib><creatorcontrib>Cho, Suk Young</creatorcontrib><creatorcontrib>Pratt, Scott Alan</creatorcontrib><creatorcontrib>Siedem, Christopher Stephen</creatorcontrib><creatorcontrib>Takeda Pharmaceutical Company Limited</creatorcontrib><title>Fused heterocyclic compounds</title><description>1 2 33 12 3 12 3 244441-4 4 There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein Ris an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; Ris an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or -NR- (wherein Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); Y, Yand Yare each an optionally substituted carbon or a nitrogen, provided that one or less of Y, Yand Yis nitrogen; and Z is a bond, -CO-, oxygen, sulfur, -SO-, -SO-, -NR-, -NR-alk-, -CONR- or -NRCO- (wherein alk is an optionally substituted Calkylene and Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); or a salt thereof or a prodrug thereof.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2012</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZJBxKy1OTVHISC1JLcpPrkzOyUxWSM7PLcgvzUsp5mFgTUvMKU7lhdLcDApuriHOHrqlxQWJJal5JcXx6UWJIMrAwtDM2NLY1JgIJQCkhyUE</recordid><startdate>20120424</startdate><enddate>20120424</enddate><creator>Aso, Kazuyoshi</creator><creator>Mochizuki, Michiyo</creator><creator>Gyorkos, Albert Charles</creator><creator>Corrette, Christopher Peter</creator><creator>Cho, Suk Young</creator><creator>Pratt, Scott Alan</creator><creator>Siedem, Christopher Stephen</creator><scope>EFH</scope></search><sort><creationdate>20120424</creationdate><title>Fused heterocyclic compounds</title><author>Aso, Kazuyoshi ; Mochizuki, Michiyo ; Gyorkos, Albert Charles ; Corrette, Christopher Peter ; Cho, Suk Young ; Pratt, Scott Alan ; Siedem, Christopher Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_081639353</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Aso, Kazuyoshi</creatorcontrib><creatorcontrib>Mochizuki, Michiyo</creatorcontrib><creatorcontrib>Gyorkos, Albert Charles</creatorcontrib><creatorcontrib>Corrette, Christopher Peter</creatorcontrib><creatorcontrib>Cho, Suk Young</creatorcontrib><creatorcontrib>Pratt, Scott Alan</creatorcontrib><creatorcontrib>Siedem, Christopher Stephen</creatorcontrib><creatorcontrib>Takeda Pharmaceutical Company Limited</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Aso, Kazuyoshi</au><au>Mochizuki, Michiyo</au><au>Gyorkos, Albert Charles</au><au>Corrette, Christopher Peter</au><au>Cho, Suk Young</au><au>Pratt, Scott Alan</au><au>Siedem, Christopher Stephen</au><aucorp>Takeda Pharmaceutical Company Limited</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Fused heterocyclic compounds</title><date>2012-04-24</date><risdate>2012</risdate><abstract>1 2 33 12 3 12 3 244441-4 4 There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein Ris an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; Ris an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or -NR- (wherein Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); Y, Yand Yare each an optionally substituted carbon or a nitrogen, provided that one or less of Y, Yand Yis nitrogen; and Z is a bond, -CO-, oxygen, sulfur, -SO-, -SO-, -NR-, -NR-alk-, -CONR- or -NRCO- (wherein alk is an optionally substituted Calkylene and Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); or a salt thereof or a prodrug thereof.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_08163935
source USPTO Issued Patents
title Fused heterocyclic compounds
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A01%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Aso,%20Kazuyoshi&rft.aucorp=Takeda%20Pharmaceutical%20Company%20Limited&rft.date=2012-04-24&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E08163935%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true